Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index61
i10-index137
Publications593
Citations18,896

Grants

16 total · 0 active

NIH #5I01BX002301-11

Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival

Amount
—
Period
2013-10-01 → 2025-12-31
PIs
2

Awarded at VETERANS HEALTH ADMINISTRATION

NIH #5R01CA227833-05

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$316K
Period
2019-04-19 → 2025-11-11
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #5P01CA129243-15

Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer

Amount
$297K
Period
2007-07-01 → 2024-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

16 total · 0 active

NIH #5I01BX002301-11

Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival

Amount
—
Period
2013-10-01 → 2025-12-31
PIs
2

Awarded at VETERANS HEALTH ADMINISTRATION

NIH #5R01CA227833-05

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$316K
Period
2019-04-19 → 2025-11-11
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #5P01CA129243-15

Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer

Amount
$297K
Period
2007-07-01 → 2024-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #3R01CA227833-05S1

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$15K
Period
2019-04-19 → 2024-06-30
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #3R01CA227833-04S1

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$51K
Period
2019-04-19 → 2024-06-30
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #5R01CA227833-04

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$320K
Period
2019-04-19 → 2024-06-30
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #5R01CA227833-03

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$344K
Period
2019-04-19 → 2024-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #5R01CA227833-02

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$347K
Period
2019-04-19 → 2024-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #1R01CA227833-01A1

Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm

Amount
$352K
Period
2019-04-19 → 2024-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #5P01CA129243-14

Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer

Amount
$303K
Period
2007-07-01 → 2023-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5P01CA129243-13

Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer

Amount
$303K
Period
2007-07-01 → 2023-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #6R01CA121210-10

Overcoming acquired resistance to EGFR inhibitors in lung cancer

Amount
$306K
Period
2007-04-01 → 2019-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #5R01CA121210-08

Overcoming acquired resistance to EGFR inhibitors in lung cancer

Amount
$294K
Period
2007-04-01 → 2017-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY

NIH #5R01CA121210-09

Overcoming acquired resistance to EGFR inhibitors in lung cancer

Amount
$303K
Period
2007-04-01 → 2016-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at VANDERBILT UNIVERSITY

NIH #5P01CA129243-12

Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer

Amount
$266K
Period
— → —
PIs
1
Est. capacity / PI
~4 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #2P01CA129243-11

Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer

Amount
$294K
Period
— → —
PIs
1
Est. capacity / PI
~4 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 52
Open author page on OpenAlex →